Calcium-channel blockers and end-stage renal disease: Pharmacokinetic and pharmacodynamic considerations

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 2, 2003, Pages 123-131

  Sica, Domenic A ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Access patency; Amlodipine; Calcium channel blockers; Diltiazem; Hypertension; Overdose; Pharmacokinetics; Verapamil

Indexed keywords

ACTIVATED CARBON; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENIDIPINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; FELODIPINE; GLUCAGON; HYPERTENSIVE FACTOR; ISRADIPINE; LOSARTAN; MANIDIPINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRATE; NITRENDIPINE; VERAPAMIL;

ANEMIA; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ASYSTOLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLETE HEART BLOCK; DIASTOLE; DISEASE CONTROL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG OVERDOSE; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; GINGIVA HYPERPLASIA; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MORTALITY; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL; VASCULAR ACCESS; VASCULAR PATENCY;

BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MAXIMUM TOLERATED DOSE; PERITONEAL DIALYSIS; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037336559     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200303000-00001     Document Type: Review

References (134)

1. Freher M, Challapalli S, Pinto JV, et al. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Prob Cardiol 1999; 24:236-240.
2. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341:1447-1457.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Amer J Kid Dis 1998; 32 (Suppl 3):S112-S119.
4. Levey AS, Beto JA, Coronando BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853-906.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
6. Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998; 32:705-719.
7. Lynn KL, McGregor DO, Moesbergen T, et al. Hypertension as a determinant of survival for patients treated with home dialysis. Kidney Int 2002; 62:2281-2287.
8. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62:1784-1790.
9. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
10. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996; 49:800-805.
11. Iseki K, Miyasato F, Tokuyama K, et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997; 51:1212-1217.
12. Zager PC, Nikolic J, Brown RH, et al. 'U' curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54:561-569.
13. London GM. Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrol Dial Transplant 2001; 16:475-478.
14. Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32:S120-S141.
15. Mailloux LU. Hypertension in chronic renal failure and ESRD: prevalence pathophysiology, and outcomes. Semin Nephrol 2001; 21:146-156.
16. Sica DA, Gehr TWB, Fernandez A. Risk-benefit ratio of angiotensin receptor blockers versus angiotensin converting enzyme inhibitors in end-stage renal disease. Drug Saf 2000; 22:350-359.
17. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1917.
18. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
19. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
20. Raine AE, Bedford L, Simpson AW, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43:700-705.
21. Rahman M, Smith MC. Hypertension in hemodialysis patients. Curr Hypertens Reports 2001; 6:496-502.
22. Misra M, Reams GP, Bauer JH. Hypertension in patients on renal replacement therapy. In: Oparil S, Weber M, editors. Hypertension. 1st ed. Philadelphia: W.B. Saunders; 2000. pp. 531-539.
23. Bennett WM, McDonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 1977; 22:499-504.
24. Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61:2157-2164.
25. Tepel M, Giet MV, Park A, Zidek W. Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond) 2002; 103:511-515.
26. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002; 62:1799-1805.
27. Saran R, Dykstra DM, Wolfe RA, et al. Association between vascular access failure and the use of specific drugs: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2002; 40:1255-1263.
28. Gradzki R, Dhingra RK, Port FK, et al. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38:1240-1244.
29. London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation 1990; 82:105-113.
30. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90:2786-2796.
31. Marchais SJ, Boussac I, Guerin AP, et al. Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. J Cardiovasc Pharmacol 1991; 18 (Suppl 5): S74-S78.
32. Cice G, Ferrara L, Tagliamonte E, et al. Incremental doses of diltiazem in patients with coronary artery disease in end-stage renal failure maintained on hemodialysis: which is the optimal dose? Cardiologia 1998; 43:1337-1343.
33. Zazgornik J, Biesenbach G, Forstenlehner M, Stummvoll K. Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy. Clin Nephrol 1997; 48:337-340.
34. Taylor AA, Sunthornyothin S. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers. Curr Hypertens Rep 1999; 1:446-453.
35. Ikeda Y, Sakemi T, Yamada M, et al. Successful combined therapy of nifedipine and diltiazem for severe hypertension in a maintenance hemodialysis patients. Clin Nephrol 1999; 51:127-128.
36. Sica DA. Combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens (Greenwich) 2001; 3:322-327.
37. Lindner UK, von Manteuffel GE, Stafunsky M. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988; 116:1814-1820.
38. Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 2000; 13:921-926.
39. Martin-Gago J, Pascual J Rodriguez-Palomares JR, et al. Complete atrioventricular blockade secondary to conventional-release verapamil in patients on hemodialysis. Nephron 1999; 83:89-90.
40. Tisler A, Akocsi K, Harshegyi I, et al. Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res 2002; 25:97-102.
41. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11:1277-1285.
42. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002; 40:1202-1210.
43. Cannella G, LaCanna G, Sandrini M, et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6:31-37.
44. Cannella G, Paoletti E, Delfino R, et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44:881-886.
45. Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90:256-261.
46. Shibasaki Y, Nishiue T, Masaki H, et al. Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho 2002; 60:1992-1998.
47. Sorrell VL. Diagnostic tools and management strategies for coronary artery disease in patients with end-stage renal disease. Semin Nephrol 2001; 21:13-24.
48. Reil GH, Lichtlen PR. Combination therapy in angina pectoris. In: Messerli F, editor. Cardiovascular Drug Therapy. 2nd ed. Philadelphia: W.B. Saunders; 1996. pp. 27-42.
49. Pritza DR, Bierman MH, Hammeke MD. Acute toxic effects of sustained-release verapamil in chronic renal failure. Arch Int Med 1991; 151:2081-2084.
50. Vaquez C, Huelmos A, Alegria E, et al. Verapamil deleterious effects in chronic renal failure. Nephron 1996; 72:461-464.
51. Hutchison SJ, Lorimer AR, Lakhdar A, McAlpine SG. Beta-blockers and verapamil: a cautionary tale. Br Med J (Clin Res Ed) 1984; 289:659-660.
52. Wayne VS, Harper RW, Laufer E, et al. Adverse interaction between beta-adrenergic blocking drugs and verapamil: report of three cases. Aust NZ J Med 1982; 12:285-289.
53. Piepho RW, Culbertson VL, Rhodes RS. Drug interactions with the calcium-entry blockers. Circulation 1987; 75 (Suppl V):V181-V194.
54. McLean AJ, Knight R, Harrison PM, et al. Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol. Amer J Cardiol 1985; 55:1628-1629.
55. Salem MM. Treatment of hypertension in the hemodialysis patient: beneficial or not? Curr Hypertens Rep 2000; 2:441-444.
56. Ansari N, Manis T, Feinfeld DA. Symptomatic atrial arrhythmias in hemodialysis patients. Ren Fail 2001; 23:71-76.
57. de Lima JJ, Vieira ML, Lopes HF, et al. Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients. Am J Hypertens 1999; 12:204-208.
58. Cice G, Tagliamonte E, Ferrara L, et al. Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis. Cardiologia 1999; 44:289-294.
59. Kayatas M, Ozdemir FN, Muderrisoglu H, Korkmaz ME. Diastolic dysfunction increases the frequency of ventricular arrhythmia in hemodialysis patients. Nephron 1999; 82:185-187.
60. Topuzovic N. Worsening of left ventricular diastolic dysfunction during long-term correction of anemia with erythropoietin in chronic hemodialysis patients: an assessment of radionuclide ventriculography at rest and exercise. Int J Card Imaging 1999; 15:233-239.
61. Laher MS, Kelly JG, Doyle GD, et al. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 1988; 12 (Suppl 7):S60-S63.
62. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Brit J Clin Pharmacol 1986; 22:21-25.
63. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22:22-31.
64. Awni WM, Halstenson CE, Nayak RK, et al. Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease. J Clin Pharmacol 1995; 35:379-383.
65. Pritchard JF, Matzke GR, Opsahl JA, et al. Effects of hemodialysis on plasma protein binding of bepridil. J Clin Pharmacol 1995; 35:137-141.
66. Hollingshead LM, Faulds D, Fitton A. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 1992; 44:835-857.
67. Grech-Belanger O, Langlois S, LeBoeuf E. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol 1988; 28:477-480.
68. Tawashi M, Marc-Aurele J, Bichet D, et al. Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure. Biopharm Drug Dispos 1991; 12:95-104.
69. Tawashi M, Marc-Aurele J, Bichet D, et al. Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers. Biopharm Drug Dispos 1991; 12:105-112.
70. Pozet N, Brazier JL, Aissa AH, et al. Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol 1983; 24:635-638.
71. Hermann P, Rodger SD, Remones G, et al. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol 1983; 24:349-352.
72. Buur T, Larsson R, Regardh CG, Aberg J. Pharmacokinetics of felodipine in chronic hemodialysis patients. J Clin Pharmacol 1991; 31:709-713.
73. Edgar B, Regardh CG, Attman PO, et al. Pharmacokinetics of felodipine in patients with impaired renal function. Br J Clin Pharmacol 1989; 27:67-74.
74. Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992; 44:251-277.
75. Schonholzer K, Marone C. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol 1992; 42:231-233.
76. Chandler MH, Schran HF, Cutler RE, et al. The effects of renal function on the disposition of isradipine. J Clin Pharmacol 1988; 28:1076-1080.
77. Fitton A, Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990; 40:31-74.
78. Ahmed JH, Grant AC, Rodger RS, et al. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991; 32:57-62.
79. Singh BN, Josephson MA. Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine. Am Heart J 1990; 119:427-434.
80. Graham DJ, Dow RJ, Hall DJ, et al. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol 1985; 20 (Suppl 1):23S-28S.
81. Lee SM, Williams R, Warnock D, et al. The effects of nicardipine in hypertensive subjects with impaired renal function. Brit J Clin Pharmacol 1986; 22:297S-306S.
82. Martre H, Sari R, Taburet AM, et al. Haemodialysis does not affect the pharmacokinetics of nifedipine. Br J Clin Pharmacol 1985; 20:155-158.
83. Kleinbloesem CH, van Brummelen P, Woittiez AJ, et al. Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. Clin Pharmacokinet 1986; 11:316-322.
84. Bogaert MG, Rosseel MT, Joos R, Boelaert J. Plasma concentrations of nifedipine in patients with renal failure. Arzneimittelforschung 1984; 34:307-308.
85. Kleinbloesem CH, van Brummelen P, van Harten J. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther 1985; 37:563-574.
86. van Bortel L, Bohm R, Mooij J. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. Eur J Clin Pharmacol 1989; 37:185-189.
87. Kirch W, Ramsch KD, Duhrsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 1984; 4:381-384.
88. Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 1989; 37:669-699.
89. Boelaert J, Valcke Y, Dammekens H, et al. Pharmacokinetics of nisoldipine in renal dysfunction. Eur J Clin Pharmacol 1988; 34:207-209.
90. Shionoiri H, Minamisawa K, Masumori S, et al. Pharmacokinetics and pharmacodynamics of nisoldipine in hypertensive patients with normal and mild to moderate impaired renal function. Arzneimittelforschung 1995; 45:785-789.
91. van Harten J, van Brummelen P, Danhof M, et al. Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. J Cardiovasc Pharmacol 1989; 13:624-629.
92. van Harten J, Burggraaf J, van Brummelen P, Breimer DD. Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing. Clin Pharmacokinet 1989; 16:55-64.
93. Kierdorf H, Muller A, Blanke PM, et al. Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure. Eur J Clin Pharmacol 1993; 45:129-134.
94. Ankermann T, Osterkamp U, Santos SR, Kirch W. Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. Eur J Clin Pharmacol 1989; 36:433-437.
95. Mikus G, Mast V, Fischer C, et al. Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. Br J Clin Pharmacol 1991; 31:313-322.
96. Soons PA, Ankermann T, Breimer DD, Kirch W. Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol 1992; 42:423-427.
97. Goa KL, Sorkin EM. Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987; 33:123-155.
98. Shah GM, Winer RL. Verapamil kinetics during maintenance hemodialysis. Am J Nephrol 1985; 5:338-341.
99. Hanyok JJ, Chow MS, Kluger J, Izard MW. An evaluation of the pharmacokinetics, pharmacodynamics and dialysability of verapamil in chronic hemodialysis patients. J Clin Pharmacol 1988; 28:831-836.
100. Beyerlein C, Csaszar G, Hollmann M, Schumacher A. Verapamil in antihypertensive treatment of patients on renal replacement therapy: clinical implications and pharmacokinetics. Eur J Clin Pharmacol 1990; 39:S35-S37.
101. Zachariah PK, Moyer TP, Theobald HM, et al. The pharmacokinetics of racemic verapamil in patients with impaired renal function. J Clin Pharmacol 1991; 31:45-53.
102. Mooy J, Schols M, v Baak M, et al. Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 1985; 28:405-410.
103. Keefe DL, Yee YG, Kates RE. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 1981; 29:21-26.
104. Muck W, Breuel HP, Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int J Clin Pharmacol Ther 1996; 34:293-298.
105. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. Clin Pharmacokinet 1992; 22:416-433.
106. Robertson DRC, Walker DG, Renwick AG, George CF. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Brit J Clin Pharmacol 1988; 25:297-305.
107. Meredith PA, Elliott HL, Ahmed JH, Reid JL. Age and the antihypertensive efficacy of verapamil: an integrated pharmacokinetic-pharmacodynamic approach. J Hypertens 1987; 5 (Suppl 5): S219-S221.
108. Elliott HL, Meredith PA, Reid JL, Faulkner JK. A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S64-S66.
109. Edgar B, Lundborg P, Regardh CG. Clinical pharmacokinetics of felodipine: a summary. Drugs 1987; 34 (Suppl 3):16-27.
110. Ellis PA, Cairns HS. Renal impairment in elderly patients with hypertension and diabetes. Quart J Med 2001; 94:261-265.
111. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40:159-168.
112. Davidson MH. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep 2000; 2:14-19.
113. Leblond F, Guevin C, Demers C, et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12:326-332.
114. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28:1317-1320.
115. Watson NA, FitzGerald CP. Management of massive verapamil overdose. Med J Austral 1991; 155:124-125.
116. Hofer CA, Smith JK, Tenholder ME. Verapamil intoxication; a literature review of overdose and discussion of therapeutic options. Am J Med 1993; 95:431-438.
117. Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: A case report and review of the literature. Amer J Med Sci 1995; 310:258-263.
118. ter Wee PM, Kremer Hovinga TKK, Uges DR, van der Geest S. 4-Aminopyridine and haemodialysis in the treatment of verapamil intoxication. Hum Toxicol 1985; 4:327-329.
119. Kuhlmann U, Schoenemann H, Muller TF, et al. Plasmapharesis in fatal overdose with verapamil. Int Care Med 1999; 25:1473.
120. Williamson KM, Dunham GD. Plasma concentrations of diltiazem and desacetyldiltiazem in an overdose situation. Ann Pharmacother 1996; 30:608-611.
121. Vargemezis V, Pasadakis P, Thodis E. The effect of calcium antagonists on the peritoneal membrane in patients on CAPD. Adv Perit Dial 1989; 5:8-11.
122. Kumano K, Go M, Ning H, Sakai T. Effects of vasodilators on peritoneal solute and fluid transport in rat peritoneal dialysis. Adv Perit Dial 1996; 12:27-32
123. Favazza A, Motanaro D, Messa P, et al. Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine. Perit Dial Int 1992; 12:287-291.
124. Panasiuk E, Pietrzak B, Obroniecka I, Wankowicz Z. The effect of verapamil on peritoneal dialysis efficiency in a clinical study. Pol Arch Med Wewn 1990; 84:296-301.
125. Vargemezis V, Pasadakis P, Thodis E. Effect of a calcium antagonist (verapamil) on the permeability of the peritoneal membrane in patients on continuous ambulatory peritoneal dialysis. Blood Purif 1989; 7:309-313.
126. Yoshimoto K, Saima S, Echizen H, et al. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1993; 40:114-117.
127. Yoshimoto K, Saima S, Nakamura Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol 1998; 50:90-93.
128. Shouda J, Nakamoto H, Sugahara S, et al. Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 1999; 15:153-155.
129. Brunet L, Miranda J, Farre M, et al. Gingival enlargement induced by drugs. Drug Saf 1996; 15:219-231.
130. Anderson JE, Yim KB, Crowell MD. Prevalence of gastroesophageal reflux disease in peritoneal dialysis and hemodialysis patients. Adv Perit Dial 1999; 15:75-78.
131. Solomon R, Dubey A. Diltiazem enhances potassium disposal in subjects with end-stage renal disease. Am J Kidney Dis 1992; 19:420-426.
132. Davidovics Y, Peer G, Cabili S, et al. Effect of verapamil on disposition of intravenous potassium in diabetic anephric uremic rats. Miner Electrolyte Metab 1993; 19:99-102.
133. Lippuner K, Zehnder HJ, Casez JP, et al. Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease. Nephrol Dial Transplant 1996; 11:70-74.
134. Taber TE, Maikranz PS, Haag BW, et al. Maintenance of adequate hemodialysis access: Prevention of neointimal hyperplasia. ASAIO 1995; 41:842-846